One area of the share market that is home to a number of quality options for investors is the mid cap space.
But which ones should you consider buying? Two to get better acquainted with are listed below:
Hipages Group Holdings Ltd (ASX: HPG)
Hipages is a leading Australia-based online platform and software as a service provider that connects tradies with residential and commercial consumers.
According to the company, over three million Australians have now used Hipages. This has provided work to over 34,000 tradies that use the platform.
Despite this, the company is understood to be capturing just 5% of total industry advertising spend. This gives it a long runway for growth over the next decade. In fact, analysts at Goldman Sachs believe the company could capture upwards of 40% to 60% in the future as the company builds out its ecosystem.
As a result, Goldman Sachs believes Hipages could be a great long term option for investors. Its analysts recently reiterated their buy rating and $3.35 price target on its shares.
Telix Pharmaceuticals Ltd (ASX: TLX)
Another mid cap share to look at is Telix. It is a clinical-stage biopharmaceutical company developing an advanced pipeline of molecularly-targeted radiation (MTR) products.
MTR is an approach which chemically links radioactive isotopes to targeting molecules specific to cancer cells.
The company notes that it has an advanced pipeline of potential therapies which are targeting clear unmet medical needs in high-value oncology segments. If these are successful, they could save countless lives and provide Telix with huge addressable markets.
One broker that is particularly positive on Telix is Wilsons. It currently has an overweight rating and $5.40 price target on the company’s shares. It notes that the company has a number of promising trials underway and was pleased to see its Illuccix product receive major market approvals earlier this year.